Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG7986) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Obinutuzumab Other Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inh Selective estrogen receptor degrader (SERD[2]) (GDC-0927/SRN-927, RG6047) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: xxx

Phase: xxx

Region: xxx

Molecule: xxx

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FR NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FR
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NC NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NC
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KR NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KR
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NZ NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NZ
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab ES NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab ES
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GA NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GA
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GB NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GB
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MI NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MI
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MO NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MO
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Vismodegib CA NCT02593760—A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
Hematology II, I Vismodegib CA
NCT02593760—A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
Tumor
Type
Phase Molecule* Location
Hematology II, I Vismodegib FL NCT02593760—A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
Hematology II, I Vismodegib FL
NCT02593760—A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
Tumor
Type
Phase Molecule* Location
Hematology II, I Vismodegib IT NCT02593760—A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
Hematology II, I Vismodegib IT
NCT02593760—A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CA NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CA
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CA NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CA
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CT NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CT
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) KR NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) KR
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) MO NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) MO
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) NY NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) NY
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) TN NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) TN
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab AL NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab AL
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab CA NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab CA
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab DE NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab DE
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab FR NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab FR
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab GB NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab GB
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab IT NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab IT
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NC NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NC
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NJ NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NJ
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NY NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NY
NCT02220842—A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab CA NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab CA
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab DE NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab DE
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab FL NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab FL
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab PL NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab PL
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab WA NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab WA
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab WV NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab WV
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) AU NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) AU
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) CA NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) CA
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) GA NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) GA
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) MA NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) MA
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) NC NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) NC
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) NY NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) NY
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) OK NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) OK
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) CA NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) CA
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) TN NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) TN
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AZ NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AZ
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CT NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CT
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FL NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FL
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) GA NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) GA
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MI NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MI
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NJ NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NJ
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Selective estrogen receptor degrader (SERD), Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) HU NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) HU
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) LA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) LA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Lung II, I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02400814—MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02400814—MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02599454—Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02599454—Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) DC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) DC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) NE NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) NE
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) WI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446) WI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Lung I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
1 of 129 clinical trials
1-4 of 129 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
Results contain non-US trial information only.

Click "OK" if you wish to proceed.
CancelOK